23
Participants
Start Date
December 30, 2022
Primary Completion Date
December 1, 2024
Study Completion Date
December 31, 2025
BGT007 Cell Injection
BGT007 cells (d0) were infused intravenously once, and the dose group was 5.0 × 10\^5cells/kg，1.0 × 10\^6cells/kg，3.0 × 10\^6cells/kg，6.0 × 10\^6cells/kg，1.0 × 10\^7cells/kg。
Fludarabine
Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
cyclophosphamide
250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
RECRUITING
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Guangzhou Bioresette Biomedical Technology Co., Ltd.
INDUSTRY
The Affiliated Hospital of Xuzhou Medical University
OTHER